Date: 2014-05-30
Type of information: Development agreement
Compound: assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types
Company: Qiagen (The Netherlands) Eli Lilly (USA- IN)
Therapeutic area: Diagnostic - Cancer - Oncology
Type agreement: development
Action mechanism:
Disease:
Details: * On May 30, 2014, Qiagen announced a collaboration with Eli Lilly and Company to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. The agreement includes the development of tests that will be based on Qiagen\'s multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test. The new collaboration is the fourth project in the two companies’ long-standing partnership. QIAGEN’s therascreen® KRAS RGQ PCR Kit has been widely adopted by laboratories since its 2012 approval by the FDA as a companion diagnostic to detect KRAS gene mutations in metastatic colorectal cancer patients. The test indicates which patients would benefit from a tailored oncology therapy marketed by Lilly and Bristol-Myers Squibb. In 2011, Qiagen and Lilly partnered to develop a companion diagnostic that evaluates a gene mutation which plays a role in some blood cancers. In 2013, QIAGEN announced a third project, building on a master collaboration agreement, to create a companion diagnostic to guide use of an undisclosed Lilly oncology compound.
Financial terms:
Latest news:
